Logo-jrip
Submitted: 17 May 2022
Accepted: 16 Jul 2022
ePublished: 02 Aug 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. Inpress.
doi: 10.34172/jrip.2022.32071
  Abstract View: 1174

Original

The effect of single dose prophylactic vancomycin before semi-permanent catheterization to prevent catheter related infection; a randomized controlled trial, phase II

Asieh Aref ORCID logo, Zohreh Zandbaf* ORCID logo, Ali Ghorbani ORCID logo, Shahla Ahmadi Halili ORCID logo

1 Department of Internal Medicine, School of Medicine, Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
*Corresponding Author: *Corresponding author: Zohreh Zandbaf, Email: , Email: farajzadeh_h@ajums.ac.ir

Abstract

Introduction: Catheter-related infections are a common complication and a major cause of morbidity and mortality in hemodialysis patients with tunneled central venous catheters. The optimal strategy for the management and prevention of catheter-related infections is unclear.

Objectives: This study is aimed to evaluate the single-dose prophylactic vancomycin efficacy before semi-permanent catheterization to prevent catheter-related infection.

Patients and Methods: This randomized double-blind controlled clinical trial was conducted on patients with chronic renal failure requiring hemodialysis and insertion of a double-lumen central venous catheter admitted to Ahvaz Golestan Hospital. The intervention group (n=30) received 1 g of vancomycin intravenously one hour before catheter insertion and the control group (n=30) received an equal amount of normal saline. The incidence of catheter-related infections and other complications for 6 months was evaluated.

Results: During the 6-month follow-up, hospitalization due to catheter-related infection and the need for antibiotic administration was observed in 9 patients (30.0%) who received vancomycin and 14 patients (46.7%) in the control group (P=0.184). Catheter extraction due to infection was observed in 4 patients of the vancomycin group (13.3%) and 6 patients of the control group (20.7%) (P=0.451). Complications other than infection were observed in four patients (13.3%) in each group (P=1.000). The mean time to onset of infection was 2.43 ±0.38 months in the control group and 3.85 ± 0.42 months in the vancomycin group (P=0.002).

Conclusion: Although a single dose of intravenous vancomycin one hour before insertion of a bi-luminal hemodialysis catheter did not show a significant effect on preventing catheter-related infections over 6 months, it significantly delayed the onset of infection.

Trial Registration: The trial protocol was approved by Iranian Registry of Clinical Trial (Ethical code: IR.AJUMS.HGOLESTAN.REC.1399.106 and IRCT code: IRCT20201206049617N1; https://www.irct.ir/trial/52832).


Implication for health policy/practice/research/medical education:

The requirement for hemodialysis is increasing worldwide with the rate of patients suffering from end-stage renal disease. Hemodialysis catheterization is accompanied by several complications including catheter-related infections, which has an effect on patients’ mortality and morbidity and is a huge economic burden on patients and society. One of the techniques to prevent this complication is antibiotics, which may be able to lower the expenses on the medical care systems.

Please cite this paper as: Aref A, Zandbaf Z, Ghorbani A, Ahmadi Halili S. The effect of single dose prophylactic vancomycin before semi-permanent catheterization to prevent catheter related infection; a randomized controlled trial, phase II. J Renal Inj Prev. 2022; x(x): e32071. doi: 10.34172/jrip.2022.32071.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 1175

Your browser does not support the canvas element.


PDF Download: 0

Your browser does not support the canvas element.